In the News

• Aug. 31, 2010
  

  Hadasit Bio Holdings raises NIS 11.5m in TASE offering

  In the second quarter of 2010, Hadasit recorded its first ever significant profit of NIS 13 million due to capital raised by portfolio company ProtAb

• Aug. 31, 2010
  

  Intec records Parkinson's clinical trial success

  The number of pills required was nearly halved.

• Aug. 29, 2010
  

  Brainsway signs distribution deal in Brazil

  The distributor will also pay Brainsway for each treatment using the Deep TMS device.

• Aug. 22, 2010
  

  Brainsway to test device against cocaine addition

  The FDA has granted investigational device exemptions for the company's Deep TMS device for this indication

• Aug. 18, 2010
  

  Healthcare co Oridion signs Japanese distribution deal

  Market sources estimate it at $2 million over the next two years

• Aug. 17, 2010
  

  Hadassah Hospital okays BiondVax study

  The biotech company will conduct a Phase II clinical trial of its universal flu vaccine

• Aug. 15, 2010
  

  Biocancell treatment gains FDA orphan drug status

  Biocancell uses targeted therapy, focusing on the H19 gene, to treat cancer while preserving healthy surrounding tissue.

• Aug. 11, 2010
  

  Chief Scientist approves Cypress-BiolineRX deal

  Cypress Biosence has paid the first $30 million to BiolineRX for the company's schizophrenia drug

• Aug. 9, 2010
  

  Cancer co Biocancell looks to Nasdaq despite going concern warning

  Biocancell had NIS 5.6 million in cash at the end of March, after a negative cash flow of NIS 1.1 million in the second quarter

• Aug. 8, 2010
  

  Brainsway looks to Nasdaq offering

  D Medical's experience last week demonstrated that obtaining a premium on the TASE market cap is not easy

• Aug. 2, 2010
  

  Chief Scientist funds Biocancell FDA trial

  As per the regular terms of Chief Scientist grants, Biocancell will pay royalties to the government if the product is commercialized.

• Jul. 14, 2010
  

  BioTime becomes Hadasit Bio partner in stem cell unit

  BioTime signed a convertible loan agreement with CellCure in the amount of $250,000.

• Jul. 14, 2010
  

  Biomed capital

  Jerusalem wants to overtake Rehovot as the country's top biomed city

• Jul. 13, 2010
  

  Morris Laster ends role as BiolineRX director

  Laster resigned as CEO at the end of 2009 and sold a block of shares in the drug development company

• Jul. 12, 2010
  

  BiolineRX progress toward Nasdaq listing

  Shareholders may vote on a reverse stock split as part of the preparations

• Jun. 29, 2010
  

  Chiasma's acromegaly drug gets FDA orphan drug status

  The company plans a Phase III trial by the end of the year

• Jun. 29, 2010
  

  Positive trial results for Brainsway anti-depression device

  The successful trial results lifted Brainsway's share price 6.11% on the TASE today

• Jun. 23, 2010
  

  Medical center in Italy to set up Brainsway clinic

  The Deep TMS Center in Milan will open in July, and will be the first of its kind.

• Jun. 21, 2010
  

  Gamida, Teva stem cell venture wins FDA fast track designation

  StemEx is being developed for patients with blood cancers who cannot find a matched related bone marrow donor.

• Jun. 20, 2010
  

  BiolineRX deal with Cypress Bioscience worth up to $365m

  Shares in BiolineRX's jumped over 12% today.

• Jun. 17, 2010
  

  Potato Power - Yissum Introduces Potato Batteries for Use in the Developing World

  Discovery published in the Journal of Renewable Sustainable Energy and Featured in Nature's Research Highlights

• Jun. 15, 2010
  

  Chiasma success in oral drug delivery trial

  The company was able to deliver an acromegaly drug normally delivered by injection.

• Jun. 14, 2010
  

  BiolineRX, US co near deal on schizophrenia drug

  The license agreement will allow completion of the R&D on BiolineRX's BL-1020.

• Jun. 10, 2010
  

  Tales From the Trauma Unit

  Life-death decision at Hadassah Medical Center

• Jun. 10, 2010
  

  Collagen Manufactured from Transgenic Tobacco Plants

  A scientist at the Hebrew University has succeeded in producing a replica of human collagen from tobacco plants

• Jun. 7, 2010
  

  Omrix rejects gov't NIS 500m patent lawsuit

  The Israeli government claims that the company's biological sealant was discovered by a government employee

• Jun. 2, 2010
  

  Oramed Pharmaceuticals Forms Joint Venture -

• May. 31, 2010
  

  Dr. Ofer Merin Represents IDF Delegation to Haiti in Receiving SWC Medal of Valor

• May. 25, 2010
  

  Yissum Introduces a Breakthrough Computational Method for Superfast Drug Discovery

• May. 18, 2010
  

  Oramed Pharmaceuticals announces that Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors

• May. 16, 2010
  

  Hadasit and Bezalel will cooperate in Medical Products' Development and Commercialization

• May. 6, 2010
  

  Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients

  ORMD-0801 Proves Safe and Tolerable in Type 2 Diabetes Subjects

• May. 6, 2010
  

  Moving closer to stem cell therapy

  An Israeli discovery allowing stem cells to be cultivated in quantities ample enough to meet the world's needs means that stem cell therapy could soon be within the reach of millions.

• Apr. 28, 2010
  

  Biocancell gains FDA nod for cancer trial progress

  83% of bladder cancer patients in the trial responded to treatment with BC-819

• Apr. 28, 2010
  

  BiolineRX earns $10m milestone payment

  Last summer, BiolineRX signed a large commercialization agreement with Ikaria Holdings.

• Apr. 27, 2010
  

  Alternate method of cell regeneration discovered by Hebrew University, Hadassah researchers holds out promise for tissue growth in aged

• Apr. 21, 2010
  

  Pharmaceutical co Rafa builds new Jerusalem facility

  The plant is part of the company's strategy to expand its exports over the next decade.

• Apr. 18, 2010
  

  Could pregnancy be the fountain of youth?

  Researchers at Jerusalem's Hebrew University are mimicking processes that occur in pregnancy and helping older animals' liver cells to regenerate better and faster.

• Apr. 15, 2010
  

  Thrombotech begins stroke treatment clinical trial

  The Phase I trial is due to be completed by the end of the year.

• Apr. 15, 2010
  

  Visionix Luneau buys Briot-Weco

  Briot-Weco makes equipment for producing spectacles lenses.

• Apr. 14, 2010
  

  Yissum, Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease

• Apr. 13, 2010
  

  Hadasit Bio brings new investors into autoimmune co ProtAb

  Hadasit Bio will also invest funds and convert debt into equity.

• Apr. 8, 2010
  

  ‘Superdominant’ mutant tomato gene could spark revolution

  Discovery by HU, New York researchers produces much higher yields and improved taste.

• Mar. 31, 2010
  

  Hadassah Breakthrough Increases the Potential to Produce the Large Quantities of Human Embryonic Stem Cells Required For Transplantation

• Mar. 25, 2010
  

  Oramed Announces Completion of Pivotal Phase 2b Clinical Trials of its Oral Insulin Capsule, ORMD-0801 for Type 2 Diabetes

• Mar. 18, 2010
  

  Intec Pharma shares jump on good Phase I study results

  The significance of the results is that one daily dose using Intec's pill can provide benefits similar to the three-times daily dose of current pills.

• Mar. 17, 2010
  

  Hadassah & Hebrew University Researchers: Pregnancy restores the regenerative capacity of aged mice

• Mar. 11, 2010
  

  Israeli diagnostics company to buy up US technologies

  It started life when the founder identified an unmet need in diagnostics. Now Israeli life science company Novamed is planning a spending spree - to buy up American companies and technologies.

• Mar. 11, 2010
  

  Hebrew U. 'Science Train' traverses Israel to mark National Science Day, Einstein's birthday

  Part of the 'Scientists on the Trains' series on Israel Railways

• Mar. 1, 2010
  

  Biocancell drops on institutional placement

  Controlling shareholders Clal Biotech, Tikro Technologies, and CSO Prof. Avraham Hochberg were not part of the placement

• Feb. 21, 2010
  

  Salt therapy is like a breath of fresh air

  A father's search to cure his son's ear infections led to an Israeli salt therapy chain that's poised to breathe salt into American air, too.

• Feb. 21, 2010
  

  Autoimmune co Tolarex gets NIS 3.5m grant

  Tolarex is developing an autoimmune therapy for graft versus host disease.

• Feb. 17, 2010
  

  Yissum Introduces a Novel System for Tracking and Analyzing Human Spatial Behavior by Monitoring People's Mobility for Tourism, Town Planning and Healthcare Applications

• Feb. 16, 2010
  

  Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.

  Dr. Amatruda is the former Senior Vice President and Franchise Head of the Diabetes and Obesity Unit at Merck & Co.

• Feb. 15, 2010
  

  The Jerusalem Development Authority Appoints Chen Levin as Executive Director of BioJerusalem

• Feb. 14, 2010
  

  Biomed co Intec's TASE offering oversubscribed

  Intec Pharma's IPO is the second IPO by a biomedical company on the TASE since 2007

• Feb. 11, 2010
  

  Committee nod implies Gamida Cell clinical trial progress

  The decision is a positive indication about StemEx's safety and its effectiveness.

• Feb. 4, 2010
  

  Intec Pharma paying high premium to underwriters

• Feb. 4, 2010
  

  Thrombotech to begin Phase I trial of stroke treatment

  The safety trial of the peptide will test its possible use for traumatic brain injury, heart attacks, lung embolisms, and blocked arteries and veins.

• Feb. 3, 2010
  

  Yissum to Collaborate with Makhteshim Agan on the Development and Commercialization of Two Environmentally-Friendly Crop Protection Technologies

• Jan. 28, 2010
  

  BiolineRX reports good results in dermatology trial

  BL-5010 cream is being tested in Europe on 60 patients who suffer from seborrheic keratosis.

• Jan. 24, 2010
  

  Protalix to trial nerve gas treatment

  The drug will probably only have to undergo Phase I trials.

• Jan. 24, 2010
  

  Brainsway sees good interim results in Alzheimer's trial

  The results indicate significantly improved cognitive function by the patients who underwent Deep TMS treatment

• Jan. 21, 2010
  

  Hebrew University Tied with Oxford University in Number of New European Research Council Grants Awarded in Past Two Years

• Jan. 19, 2010
  

  Chiasma signs strategic agreement with Novartis

  Novartis has also invested in the oral drug delivery system developer via MPM Capital.

• Jan. 19, 2010
  

  Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801

  Key Trial for Oral Insulin with Expected Results at the End of Q1 of 2010

• Jan. 18, 2010
  

  European Medicines Agency (EMA) Waives Requirement to Test StemEx® in Paediatric Patients 17 Years of Age and Under

  The international study of StemEx, an experimental treatment for leukemia, lymphoma and MDS, is now enrolling at clinical sites in Italy, Hungary, Spain, Israel and the U.S.

• Jan. 17, 2010
  

  BiolineRX reports further success in schizophrenia trial

  Shares in the company rose sharply this morning.

• Jan. 6, 2010
  

  Autoimmune therapy co Tolarex reports positive trial results

  Hadasit Bio will extend the firm NIS 1 million in new funding.

• Jan. 3, 2010
  

  Brainsway shares jump on schizophrenia trial results

  One patient, who had heard voices daily for years, no longer had auditory hallucinations after the second treatment.